UK guidelines for the management of bone sarcomas

Area of Science:

• Orthopedic Oncology
• Sarcoma Research
• Clinical Practice Guidelines

Background:

• The British Sarcoma Group (BSG) guidelines for 2016 required an update to reflect current best practices.
• There is a need for standardized clinical care for primary malignant bone tumours (PMBT) and giant cell tumours of bone (GCTB) in the UK.
• Effective treatments and service delivery models are essential for optimal patient outcomes.

Purpose of the Study:

• To provide an updated reference standard for the clinical care of UK patients diagnosed with PMBT and GCTB.
• To recommend effective treatments and support management and service delivery decisions.
• To establish a consensus-based document for the British Sarcoma Group in 2024.

Main Methods:

• Development of guidelines based on a consensus amongst British Sarcoma Group members in 2024.
• Inclusion of key recommendations for diagnosis, referral, and management.
• Provision of treatment recommendations for various tumor types and disease stages (localized, metastatic, recurrent).

Main Results:

• Bone pain or a palpable mass should always prompt further investigation for potential bone tumors.
• Patients with suspected PMBT or GCTB require referral to specialist centers and management by accredited bone sarcoma multidisciplinary teams.
• Specific treatment recommendations are outlined for major tumor types and disease statuses, alongside suggested follow-up schedules.

Conclusions:

• These updated guidelines provide a crucial reference for the management of primary bone tumors in the UK.
• Adherence to specialist referral and multidisciplinary team care is paramount for patients with PMBT and GCTB.
• The guidelines aim to ensure effective and accessible treatment options are available for bone sarcoma patients.